Skip to main content

Table 1 Participant Characteristics at Baseline

From: The neutrophil to lymphocyte ratio associates with markers of Alzheimer’s disease pathology in cognitively unimpaired elderly people

 

ADNI

NYU

p

 

n

111

190

  

Age (Mean, SD)

73.79 (6.43)

61.53 (10.94)

 < 0.001

***

Sex (m) (n, %)

55 (49.5)

70 (36.8)

0.042

*

Education (Mean, SD)

16.25 (2.74)

16.75 (2.14)

0.082

 

Race (white) (n, %)

95 (85.6)

174 (91.6)

0.152

 

APOE4 (n, %)

32 (28.8)

58 (30.5)

0.857

 

Days Between Exams (Mean, SD)

81.73 (99.10)

28.33 (71.93)

 < 0.001

***

BMI (Mean, SD)

27.94 (4.65)

25.79 (4.39)

 < 0.001

***

History of Hypertension (n, %)

53 (47.7)

31 (16.3)

 < 0.001

***

Diabetic (n, %)

2 (1.8)

5 (2.6)

0.949

 

Cognitive Decline (n, %)

11 (9.9)

8 (4.2)

0.086

 

CSF Aβ Positive (n, %)

38 (34.2)

38 (20.0)

0.009

**

CSF Aβ (Mean, SD)*

211 (55)

714 (232)

NA

 

CSF T-Tau (Mean, SD)*

69 (33)

275 (146)

NA

 

CSF P-Tau (Mean, SD)*

30 (21)

46 (18)

NA

 

NLR (Mean, SD)

2.23 (0.98)

2.09 (0.87)

0.209

 
  1. All included subjects had complete accounts of the above data. Categorical variable differences were calculated using chi-squared tests, and continuous variable differences were calculated using ANOVA tests. APOE4 positivity was defined by the presence of at least one APOE4 allele. CSF Aβ positivity was defined by the respective cut-off threshold for each cohort (NYU, < 469.5 pg/mL; ADNI, < 192 pg/mL). Days Between Exams was calculated as the number of days between the cross-sectional CSF exam and CBC exam from which the NLR was calculated. Cognitive decline refers to subjects who were given a diagnosis of MCI or AD during follow-up CSF collection, and this binary variable was included as an additional adjustment in the longitudinal analysis
  2. *CSF measures were obtained and scaled using separate procedures for each cohort, including the use of different antibody assays, so cohort differences could not be calculated (see Materials and Methods)